Published in Cancer Res on October 01, 1985
Synthetic methods for the preparation of platinum anticancer complexes. Chem Rev (2013) 1.11
Anticancer effects of 6-o-palmitoyl-ascorbate combined with a capacitive-resistive electric transfer hyperthermic apparatus as compared with ascorbate in relation to ascorbyl radical generation. Cytotechnology (2011) 0.79
Carcinostatic effects of diverse ascorbate derivatives in comparison with aliphatic chain moiety structures: Promotion by combined hyperthermia and reduced cytotoxicity to normal cells. Oncol Lett (2012) 0.78
Preparation of lymphocyte-activating factor from continuous murine macrophage cell lines. Cell Immunol (1977) 2.81
Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res (1968) 2.67
Partial purification of human lymphocyte-activating factor (LAF) by ultrafiltration and electrophoretic techniques. J Immunol (1977) 2.58
High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer (1977) 2.07
Overexpression of metallothionein confers resistance to anticancer drugs. Science (1988) 2.03
Characteristics of traffic crashes among young, middle-aged, and older drivers. Accid Anal Prev (1999) 1.89
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst (1992) 1.79
Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest (1990) 1.57
Glass needle-mediated microinjection of macromolecules and transgenes into primary human blood stem/progenitor cells. Blood (2000) 1.55
Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther (1971) 1.44
Venous thrombosis associated with the placement of peripherally inserted central catheters. J Vasc Interv Radiol (2001) 1.40
A revised scheme for the evaluation of automatic instruments for use in clinical chemistry. Ann Clin Biochem (1974) 1.40
Treatment of spider veins with the 595 nm pulsed-dye laser. J Am Acad Dermatol (1998) 1.39
Toxicity of E. coli L-asparaginase in man. Cancer (1970) 1.36
New platinum complexes with anti-tumour activity. Chem Biol Interact (1972) 1.35
Cancer chemotherapeutic agents. CA Cancer J Clin (1977) 1.15
Proceedings: Combination chemotherapy of multiple myeloma with alkeran, cytoxan, vincristine, prednisone, and BCNU. Cancer (1974) 1.15
Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Res (1999) 1.12
Synthesis, characterization and cytotoxicity of new platinum(IV) axial carboxylate complexes: crystal structure of potential antitumor agent [PtIV(trans-1R,2R-diaminocyclohexane)trans(acetate)2Cl2]. Bioorg Med Chem (2000) 1.10
Nephrotoxicity of cis-dichlorodiammineplatinum(II). Cancer Treat Rep (1980) 1.10
Adriamycin--an antitumor antibiotic in the treatment of neoplastic diseases. Cancer (1973) 1.10
Dihydrofolate reductase from Trypanosoma equiperdum. I. Isolation, partial purification, and properties. Mol Pharmacol (1967) 1.09
A recommended scheme for the evaluation of kits in the clinical laboratory. Ann Clin Biochem (1980) 1.09
Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res (1999) 1.08
Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med (1972) 1.07
Quinacrine (Atabrine) in the treatment of neoplastic effusions. Ann Intern Med (1967) 1.07
Use of allopurinol in preventing hyperuricemia in leukemia and lymphoma. Cancer (1966) 1.06
Synthesis and antitumor evaluations of symmetrically and unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene-9,10-diones. J Med Chem (1991) 1.06
Long-term sun exposure alters the collagen of the papillary dermis. Comparison of sun-protected and photoaged skin by northern analysis, immunohistochemical staining, and confocal laser scanning microscopy. J Am Acad Dermatol (1996) 1.04
Carbocyclic analogues of the potent cytidine deaminase inhibitor 1-(beta-D-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine). J Med Chem (1998) 1.03
Adriamycin in advanced urinary tract cancer: experience in 42 patients and review of the literature. Cancer (1977) 1.03
Occlusive ligature and standardized fenestration of a Baerveldt tube with and without antimetabolites for early postoperative intraocular pressure control. Ophthalmology (1998) 1.02
Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1. Biochem Pharmacol (1993) 1.01
Transient complementation of xeroderma pigmentosum cells by microinjection of poly(A)+ RNA. Proc Natl Acad Sci U S A (1984) 1.00
Comparative properties of schistosomal and filarial dihydrofolate reductases. Biochem Pharmacol (1972) 0.98
Urinary metabolites in congenital hyperuricosuria. Science (1967) 0.98
B16 murine melanoma and aging: slower growth and longer survival in old mice. J Natl Cancer Inst (1984) 0.97
Effects of hydroxyurea on polyoma virus replication. Cancer Res (1968) 0.97
Glycolic acid treatment increases type I collagen mRNA and hyaluronic acid content of human skin. Dermatol Surg (2001) 0.96
Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer (2006) 0.96
Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol (1994) 0.96
Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog. Science (1985) 0.95
Clinical toxicologic and pharmacologic studies of gallium nitrate. Cancer (1979) 0.95
Synthesis of 1,3-diazepin-2-one nucleosides as transition-state inhibitors of cytidine deaminase. J Med Chem (1980) 0.95
Induction of interferon in human subjects by poly I:C. Proc Soc Exp Biol Med (1971) 0.94
2,4-Diaminothieno[2,3-d]pyrimidine analogues of trimetrexate and piritrexim as potential inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J Med Chem (1993) 0.94
Chronic sun exposure alters both the content and distribution of dermal glycosaminoglycans. Br J Dermatol (1996) 0.93
Clinical experience with L-asparaginase. Recent Results Cancer Res (1970) 0.93
Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside. Cancer Treat Rep (1979) 0.93
Simultaneous grayscale and subharmonic ultrasound imaging on a modified commercial scanner. Ultrasonics (2011) 0.92
Effect of cytotoxic monoclonal antibody depletion of T-lymphocyte subpopulations on bleomycin-induced lung damage in C57BL/6J mice. Toxicol Appl Pharmacol (1989) 0.92
Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. J Med Chem (1986) 0.92
Mechanisms of asbestos-induced nitric oxide production by rat alveolar macrophages in inhalation and in vitro models. Free Radic Biol Med (1998) 0.92
Glaucoma screening by means of an optic disc grid. Br J Ophthalmol (1983) 0.92
Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones. Cancer Lett (1995) 0.91
Alteration of bronchoalveolar lavage cell populations following bleomycin treatment in mice. Toxicol Appl Pharmacol (1989) 0.91
Hyperuricemia in neoplastic disease in children: prevention with allopurinol, a xanthine oxidase inhibitor. Pediatrics (1968) 0.91
Cyclic urea nucleosides. Cytidine deaminase activity as a function of aglycon ring size. J Med Chem (1981) 0.90
Combination chemothereapy with cis-diamminedichloroplatinum (II) and bleomycin in tumors of the head and neck. Oncology (1975) 0.90
Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J Lab Clin Med (1996) 0.90
Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man. Cancer Treat Rep (1977) 0.90
Specific in vivo and in vitro antibody response to tetanus toxoid immunization. Clin Exp Immunol (1982) 0.90
Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother (1992) 0.89
Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother Rep (1973) 0.89
Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol (2003) 0.89
Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. J Clin Oncol (1993) 0.89
Nitric oxide modulates lymphocyte proliferation but not secretion of IL-2. Immunol Invest (1993) 0.88
Presence and properties of dihydrofolate reductases within the genus Crithidia. Biochim Biophys Acta (1969) 0.88
Effects of folate deficiency on the metastatic potential of murine melanoma cells. Cancer Res (1988) 0.88
Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Biochem Pharmacol (1995) 0.87
Ultraviolet radiation activates the human elastin promoter in transgenic mice: a novel in vivo and in vitro model of cutaneous photoaging. J Invest Dermatol (1995) 0.87
Visualization of interphase chromosomes. J Cell Sci (1977) 0.86
Study of purine metabolism in a xanthinuric female. J Clin Invest (1968) 0.86
Clinical and laboratory studies of an unusual carcinoid tumour. Br J Surg (1970) 0.86
Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes. J Med Chem (1990) 0.86
Furanose-pyranose isomerization of reduced pyrimidine and cyclic urea ribosides. J Med Chem (1986) 0.86
Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos (1986) 0.86
Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application. J Med Chem (1998) 0.86
Toxicity and antitumor activity of cis-bis-cyclopentenecarboxylato-1,2-diaminocyclohexane platinum(II) encapsulated in multilamellar vesicles. Cancer Res (1986) 0.85
13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst (1993) 0.85
Chromatin decondensation and DNA synthesis in human sperm activated in vitro by using Xenopus laevis egg extracts. J Exp Zool (1987) 0.85
Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance. J Inorg Biochem (1999) 0.85
Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands. Cancer Res (1993) 0.85
The role of DNA repair in resistance of L1210 cells to isomeric 1,2-diaminocyclohexaneplatinum complexes and ultraviolet irradiation. Mutat Res (1991) 0.84
Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Cancer Res (1990) 0.84
Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. Biochem Pharmacol (1993) 0.84
Comparative activity and properties of lactate dehydrogenase, xanthine dehydrogenase, and dihydrofolate reductase in normal and Brugia pagangi-infected Aedes aegypti. J Parasitol (1977) 0.83
Homoharringtonine: a phase I evaluation. Invest New Drugs (1985) 0.83
Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity. Invest New Drugs (1989) 0.83
Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anticancer Drugs (1993) 0.83
Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. J Clin Oncol (1995) 0.83
In vitro activation of human sperm induced by amphibian egg extract. Exp Cell Res (1985) 0.83
Bimodal effects of 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) on cell cycle checkpoints. Clin Cancer Res (2001) 0.83
Xanthine oxidase-mediated oxidation of epinephrine. Biochem Pharmacol (1971) 0.82
Effect of disulfiram (tetraethylthiuram disulfide) amd diethyldithiocarbamate on the bladder toxicity and antitumor activity of cyclophosphamide in mice. Cancer Res (1982) 0.82
Cimetidine and the immune response. I. In vivo augmentation of nonspecific and specific immune response. Clin Immunol Immunopathol (1983) 0.82
Chemotherapy of gastrointestinal cancer. Cancer (1972) 0.82
Gastric xanthelasma in hyperplastic gastric polyposis. Arch Pathol Lab Med (1989) 0.82